進行性骨化性線維異形成症(FOP)の参加者におけるアンデカリキシマブの研究 (ANDECAL)
進行性骨化性線維異形成症(FOP)の参加者におけるアンデカリキシマブの有効性と安全性を評価するための、非盲検延長(OLE)を用いた第2/3相、グローバル、多施設共同、ランダム化、二重盲検、プラセボ対照、2部構成試験
This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP.
The study is looking at several research questions, including:
- Safety of andecaliximab in participants with FOP
- Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO)
- Whether andecaliximab reduces the number or severity of flare-ups
- Pharmacokinetics/pharmacodynamics (PK/PD): How much study drug is in your blood at different times and its impact on blood biomarker(s)
- Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
調査の概要
詳細な説明
The ASH-FOP-201 Study consists of 2 parts: Part 1 is a Lead-in Study to assess safety, PK/PD and preliminary efficacy; Part 2 is the Main Study, a Phase 2/3 randomized, double-blind, placebo-controlled trial.
Part 1 is composed of Part 1a, a Na18F positron emission tomography (PET)/computed tomography, less head (CT) Study in up to 6 participants age ≥ 15 years, and Part 1b, a flare-up Study in up to 6 participants ≥ 12 years of age. Participants enrolled in Part 1 will be randomized to one of two dose levels for 13 weeks. Participants in Part 2 will be randomized to one of two dose levels of drug vs. placebo during the 52 week trial. All participants in Part 1 or Part2 will receive study drug in the extension period of the trial.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究場所
-
-
California
-
San Francisco、California、アメリカ、94143
- University of California San Francisco (UCSF)
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania - Perelman Center for Advanced Medicine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria (Part 1a, 1b, and 2):
- Participant and/or guardian able and willing to give informed consent and/or assent as applicable, and willing to adhere to the visits schedule and study procedures.
- Clinical diagnosis of FOP including congenital malformation(s) consistent with FOP (e.g., of the great toes), and either episodic soft tissue swelling consistent with an FOP flare-up and/or progressive HO.
4. CAJIS score of ≤19. 5. Disease activity within 1 year of screening visit. Disease activity is defined as physician confirmed flare-up like symptoms or clinical progression including newly identified HO or worsening joint function.
6. Able to understand, undergo, and perform all protocol related procedures, including low-dose WBCT-LH scan without sedation. Assistance from a caregiver is allowed.
7. Agree to provide access to all relevant current and historical medical records (including radiographs or radiographic records) and growth records.
Inclusion Criteria (Part 1a only):
- Male or female ≥ 15 years of age.
- Serum creatinine ≤ upper limit of normal for age.
- No open growth plates on bilateral PA hand/wrist or AP knee films at baseline
- Able to receive IV radiotracer [both IV access and no history of a reaction to radiotracer].
- No use of bisphosphonates or bone active agent within the past year.
- At least 1 active HO lesion at baseline per Na18F PET/CT
Additional inclusion criteria apply including those listed above for all parts of the study.
Inclusion Criteria (Part 1b only):
-
Male or female ≥12 years of age.
-
History of multiple flare-up episodes within the past 6 months (to be reviewed and confirmed as qualifying by the PI together with the Sponsor). Qualifying flare-up episodes include any of the following:
- At least 3 qualifying flare-ups in the past 6 months each with continuous symptoms for at least 1 week
- Migratory flare-up swellings across the back
- Multiple flare-up episodes the sum of which lasted at least 21 days The timing of the individual flare-ups can be overlapping; they may be ongoing at the time of enrollment or resolved.
-
The qualifying flare-ups must involve at least 2 of the following flare-up symptoms:
- Pain
- Soft tissue swelling
- Warmth
- Redness
- Joint stiffness
- Decreased range of motion
Additional inclusion criteria apply including those listed above for all parts of the study.
Inclusion Criteria (Part 2 only):
- Initial enrollment age requirement is ≥12 years
- Enrollment may be extended to participants ≥6 years of age after safety in adult and participants age 12-17 years has been established.
- Enrollment of participants ≥2 to <6 years of age will commence after safety in adult and participants ≥6 years of age has been established.
Additional inclusion criteria apply including those listed above for all parts of the study.
Exclusion Criteria:
-
Body weight <10kg
-
Known non-healed fracture at time of Study Day 1.
-
Planned surgery within the timeframe of the study duration or still recovering from recent surgery.
-
Respiratory compromise that requires use of supplemental oxygen.
-
Participant has
- Known monogenic disorder other than FOP.
- Bone or mineral disorder unrelated to FOP.
-
Malignancy (within the past 5 years, except non-melanoma skin cancer, cervical carcinoma in situ, or ductal carcinoma in situ [DCIS]).
-
Known active infection (including fungal, bacterial, mycobacterial, or viral infection including COVID19)
-
Uncontrolled hypoparathyroidism or hyperparathyroidism.
-
Per participant report or chart review (no testing required): Uncontrolled hyperthyroidism
-
Use of the following medication:
- Systemic corticosteroids with a prednisone equivalent of >10mg/day within 1 week of Study Day 1. If the participant requires chronic use of >10mg/day prednisone equivalent of corticosteroids, eligibility will be discussed with the Sponsor.
- NSAIDs of higher than doses recommended by the May 2022 ICCFOP guidelines within 1 week of Study Day 1. If the participant requires chronic use of NSAIDs at doses higher than those recommended by the May 2022 ICCFOP guidelines doses, eligibility will be discussed with the Sponsor.
- Current or chronic use of tetracycline drugs (e.g., tetracycline, demeclocycline, doxycycline, or minocycline).
-
Chronic use of any of unproven therapies for FOP.
-
Palovarotene
- Within 1 month of Study Day 1 for all participants
- Within 2 years of Study Day 1 for female participants <8 years of age Or male participants <10 years of age
-
Treatment with another investigational product within 5 half lives of last dose at the time of Study Day 1 or 1 month, whichever is longer.
-
History of allergy or hypersensitivity to andecaliximab or its excipients.
-
Significant current laboratory abnormalities
-
Breastfeeding, pregnant, or planning pregnancy.
-
Those of childbearing potential unwilling to agree to abstain from sexual activity that could result in pregnancy or unwillingness to use acceptable birth control during the study and for 90 days after the last dose.
-
Simultaneous participation in another clinical trial involving another investigational product.
-
Significant medical condition or disability or biochemical or hematologic abnormalities that in the opinion of the Investigator would expose the participant to undue risk, prevent the conduct of study procedures, or confound the study results.
Note: Other protocol defined Inclusion/Exclusion Criteria apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1a: PET/CT Study
a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) Study to assess the impact of two dose levels of andecaliximab administered subcutaneously (SC), once-a-week (QW) in participants age ≥ 15 years, with FOP on a number of outcomes including Safety, Pharmacokinetic (PK) and pharmacodynamic (PD) and the change from baseline of Na18F uptake in HO lesions by PET/CT scan, and Patient Reported Outcomes (PROs). |
Dose level A or B Dose level A or B (or age adjusted dose) |
|
実験的:Part 1b: Flare-up Study
a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) study to assess the impact of two dose levels of andecaliximab administered SC QW in participants ≥12 years of age with a recent history of frequent flare-up episodes on a number of outcomes including safety, PK/PD, and flare-up incidence and symptoms and PROs. |
Dose level A or B Dose level A or B (or age adjusted dose) |
|
プラセボコンパレーター:Part 2: Main Study
1-year (52-week) double-blind (Investigator, participant, and sponsor all blinded), placebo-controlled study of andecaliximab Dose level A or B (or age adjusted) SC QW or placebo in pediatric and adult patients with FOP. The Main Study will enroll approximately 80 participants, randomized in a 1:1:1 ratio to andecaliximab Dose level A or B (or age adjusted) SC QW or placebo. |
Dose level A or B Dose level A or B (or age adjusted dose) Blinded |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of New HO Lesions as Assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)]
時間枠:Week 27 and 53
|
Low dose WBCT-LH (whole body CT less head) is used to create detailed images of soft tissues and bones. |
Week 27 and 53
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
WBCT-LH で評価した H2O 量の経時的変化 [全身、コンピュータ断層撮影 (CT)、頭部を含まない (頭部未満)]
時間枠:27週目と53週目
|
27週目と53週目
|
|
|
参加者によって報告された再発の数
時間枠:14、27、53週目
|
14、27、53週目
|
|
|
参加者によって報告され、主任研究者によって確認された再発の数
時間枠:14、27、53週目
|
14、27、53週目
|
|
|
Percent change from baseline in Na18F standardized uptake value maximum (SUVmax) of up to 7 individual HO lesion(s) per participant active at baseline as assessed by Na18F PET/CT (Part 1a).
時間枠:Week 14
|
SUV max is the SUV of the most intense voxel within a region of interest. |
Week 14
|
|
Change in HO volume over time as assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)] (Part 1a)
時間枠:Week 14
|
Low dose WBCT-LH (whole body CT less head) is used to create detailed images of soft tissues and bones. In Part 1a, the WBCT-LH scan will be acquired as part of the PET/CT scan at baseline and Week 14. |
Week 14
|
|
Number of days during which a flare-up is experienced by the participant as reported by the participant
時間枠:Week 14, 27 and 53
|
Flare-up defined as having at least two of the following symptoms: pain, soft tissue swelling, warmth, redness, joint stiffness, or decreased range of motion. |
Week 14, 27 and 53
|
|
Change in patient joint involvement as assessed by Investigator using Cumulative Analog Joint Involvement Scale (CAJIS)
時間枠:Week 27 and 53
|
CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30. |
Week 27 and 53
|
|
Change in patient quality of life as assessed by the EuroQol 5 dimensions questionnaire with a 5-level scale (EQ-5D-5L)
時間枠:Week 27 and 53
|
EQ-5D-5L measures: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. |
Week 27 and 53
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
時間枠:Week 27 and 53
|
Number of participants with Treatment-Emergent Adverse Events (AE) (TEAEs), i.e., adverse events not present at baseline or exacerbation of a pre-existing condition during the on-treatment period will be reported. |
Week 27 and 53
|
|
Number of Participants With Serious Treatment-Emergent Adverse Events (Serious TEAEs)
時間枠:Week 27 and 53
|
Number of participants with Serious Treatment-Emergent Adverse Events (AE) (TEAEs), i.e, required initial/prolonged in-patient hospitalization, death, life-threatening, persistent/significant disability/incapacity, congenital anomaly/birth defect, considered as a medically important event. |
Week 27 and 53
|
|
Number of Participants With TEAEs by Severity
時間枠:Week 27 and 53
|
Severity of TEAEs will be graded as follows: Mild: Does not interfere in a significantly with functioning. Moderate: Causes some impairment of functioning but is not hazardous to health. Severe: Significant impairment or incapacitation; hazardous to one's health. Number of participants with TEAEs by severity will be reported. |
Week 27 and 53
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Lounev V, Groppe JC, Brewer N, Wentworth KL, Smith V, Xu M, Schomburg L, Bhargava P, Al Mukaddam M, Hsiao EC, Shore EM, Pignolo RJ, Kaplan FS. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice. J Bone Miner Res. 2024 May 2;39(4):382-398. doi: 10.1093/jbmr/zjae029.
- Wein MN, Yang Y. Actionable disease insights from bedside-to-bench investigation in fibrodysplasia ossificans progressiva. J Bone Miner Res. 2024 May 2;39(4):375-376. doi: 10.1093/jbmr/zjae044. No abstract available.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- ASH-FOP-201
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Redacted Protocol and SAP will be made available.
IPD 共有時間枠
After completion of the Biologics License Applications (BLA) and all participants have completed the one year extension.
IPD 共有アクセス基準
Not decided at this time
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。